AI-generated summary
The authors report a randomized controlled trial of photobiomodulation for preventing recurrent herpes labialis, comparing two laser doses with a placebo over 6 months of treatment and 2 years of follow-up. They report that both laser groups had fewer recurrences and less severe lesions than placebo, with the 1 J per point group showing the most favorable results. No side effects were reported, though the abstract does not state how the findings were measured or how large the differences were.
- Participants
- 158
- Who or what was studied
- Volunteers with recurrent herpes labialis
- Limits stated in the abstract
- The abstract does not report wavelengths, the specific measures used, or effect sizes, so the strength of the findings cannot be fully judged.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.